Decoy Therapeutics price to sales ratio DCOY

Market value divided by revenue over the last twelve months, since 2017.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 18.7×; Jul 2022
10-year median: 9.6×
10-year range: 2.0× to 107×
Peer median: 0.0×

Decoy Therapeutics' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Jul 2022, at 18.7×.

On the days it had one over the last ten years, its median was 9.6×, from 2.0× in Mar 2020 to 107× in Mar 2018.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2022	18.7×	5.0×	21.5×
2021	6.8×	4.6×	13.3×
2020	3.8×	2.0×	11.9×
2019	12.2×	4.7×	19.1×
2018	5.7×	5.7×	107×
2017	48.6×	34.1×	78.2×

Against its peers

Companies in Drug Manufacturers - General nearest Decoy Therapeutics' size, closest first, today.

Company	Price to sales ratio
DCOYDecoy Therapeutics	n/m
SBFMSunshine Biopharma	0.0×
JAGXJaguar Health	0.0×
LABTLakewood-Amedex Biotherapeutics	n/m
NXTSNexentis Technologies	n/m
VBIOValion Bio	n/m
ARTLArtelo Biosciences	n/m
LNAILunai Bioworks	n/m
GNPXGenprex	n/m
GOVXGeoVax Labs	n/a
ONCOOnconetix	n/m
Peer median	0.0×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Decoy Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.